SITAPRIDE M 100/500

About

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by enhancing the body's natural ability to regulate blood glucose levels by increasing active incretin hormone concentrations. These hormones stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity in peripheral tissues. This combination therapy is indicated for adults with type 2 diabetes mellitus to improve glycemic control when diet and exercise alone are insufficient or when monotherapy with either agent is inadequate. The synergistic action of sitagliptin and metformin addresses multiple pathophysiological defects of type 2 diabetes, leading to more effective and sustained blood sugar management.

Uses

• Treatment of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as an adjunct to diet and exercise.
• When monotherapy with metformin or sitagliptin is inadequate.

Directions For Use

Take this medication orally, usually once or twice daily with meals, as prescribed by your healthcare provider. Swallow the tablet whole with water.

Benefits

• Effective reduction in HbA1c levels.
• Dual mechanism of action for comprehensive control.
• Low risk of hypoglycemia when used as monotherapy.
• Potential for modest weight reduction (Metformin).
• Enhances insulin sensitivity and secretion.
• Convenient fixed-dose combination therapy.

Side Effects

• Gastrointestinal upset (nausea, diarrhea)
• Abdominal discomfort
• Headache
• Upper respiratory tract infection
• Nasopharyngitis
• Joint pain
• Hypoglycemia (especially with other antidiabetics)
• Pancreatitis (rare)
• Lactic acidosis (rare, Metformin)
• Vitamin B12 deficiency (Metformin)
• Allergic reactions (e.g., rash)
• Kidney problems (rare)

Safety Measures

• Alcohol - Excessive alcohol intake should be avoided due to an increased risk of lactic acidosis, a serious complication associated with metformin, and potential effects on blood glucose regulation.
• Pregnancy - Not generally recommended during pregnancy. Consult a doctor; the potential benefits must be weighed against risks. Insulin is often the preferred treatment for gestational diabetes.
• Breastfeeding - Metformin passes into breast milk in small amounts; sitagliptin's presence is unknown. Use with caution and under medical guidance, considering potential infant exposure.
• Liver - Contraindicated in severe hepatic impairment due to the increased risk of lactic acidosis with metformin. Sitagliptin may require dose adjustment in moderate to severe liver disease.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to metformin accumulation. Sitagliptin dosage must be adjusted based on renal function.
• Lung - No specific contraindications for lung conditions, but caution is advised in conditions predisposing to hypoxia, which can increase the risk of lactic acidosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.